Nuveen Asset Management LLC Invests $11.53 Million in Global Blood Therapeutics Inc (NASDAQ:GBT)

Nuveen Asset Management LLC bought a new position in Global Blood Therapeutics Inc (NASDAQ:GBT) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 219,203 shares of the company’s stock, valued at approximately $11,530,000. Nuveen Asset Management LLC owned approximately 0.37% of Global Blood Therapeutics as of its most recent SEC filing.

Several other institutional investors and hedge funds have also bought and sold shares of GBT. Steward Partners Investment Advisory LLC bought a new position in shares of Global Blood Therapeutics in the second quarter valued at approximately $27,000. Captrust Financial Advisors bought a new stake in Global Blood Therapeutics during the second quarter valued at approximately $42,000. NumerixS Investment Technologies Inc bought a new stake in Global Blood Therapeutics during the second quarter valued at approximately $63,000. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in Global Blood Therapeutics by 17.3% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,265 shares of the company’s stock valued at $172,000 after purchasing an additional 482 shares during the last quarter. Finally, Tower Research Capital LLC TRC lifted its position in Global Blood Therapeutics by 3,272.5% during the second quarter. Tower Research Capital LLC TRC now owns 3,440 shares of the company’s stock valued at $181,000 after purchasing an additional 3,338 shares during the last quarter. Hedge funds and other institutional investors own 97.99% of the company’s stock.

In other Global Blood Therapeutics news, insider Lesley Ann Calhoun sold 2,765 shares of the business’s stock in a transaction on Wednesday, September 11th. The shares were sold at an average price of $54.36, for a total transaction of $150,305.40. Following the transaction, the insider now directly owns 887 shares of the company’s stock, valued at approximately $48,217.32. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Deval L. Patrick sold 5,357 shares of the business’s stock in a transaction on Tuesday, October 8th. The shares were sold at an average price of $45.05, for a total transaction of $241,332.85. Following the transaction, the director now directly owns 5,357 shares in the company, valued at $241,332.85. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 11,371 shares of company stock worth $549,865. 4.30% of the stock is owned by insiders.

Shares of NASDAQ GBT opened at $46.53 on Friday. The company has a quick ratio of 16.79, a current ratio of 16.79 and a debt-to-equity ratio of 0.03. Global Blood Therapeutics Inc has a 52 week low of $30.15 and a 52 week high of $64.94. The firm’s fifty day moving average is $49.66 and its 200 day moving average is $54.28.

Global Blood Therapeutics (NASDAQ:GBT) last issued its earnings results on Wednesday, August 7th. The company reported ($1.01) EPS for the quarter, missing the consensus estimate of ($0.96) by ($0.05). During the same period in the prior year, the firm earned ($0.78) EPS. Equities research analysts expect that Global Blood Therapeutics Inc will post -4 EPS for the current fiscal year.

Several equities research analysts have issued reports on GBT shares. Cantor Fitzgerald set a $110.00 target price on shares of Global Blood Therapeutics and gave the company a “buy” rating in a research report on Friday, June 14th. ValuEngine lowered shares of Global Blood Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, October 2nd. Morgan Stanley set a $60.00 target price on shares of Global Blood Therapeutics and gave the company a “hold” rating in a research report on Friday, August 9th. Wedbush reiterated a “buy” rating and set a $120.00 target price on shares of Global Blood Therapeutics in a research report on Wednesday. Finally, HC Wainwright reiterated a “buy” rating and set a $150.00 target price on shares of Global Blood Therapeutics in a research report on Wednesday. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and ten have issued a buy rating to the company. The stock currently has an average rating of “Buy” and an average price target of $90.42.

Global Blood Therapeutics Company Profile

Global Blood Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities. It is developing its lead product candidate, voxelotor, an oral, once-daily therapy for sickle cell disease (SCD). The company is evaluating voxelotor in SCD in a Phase III clinical trial in adult and adolescent patients with SCD.

Read More: What is Put Option Volume?

Want to see what other hedge funds are holding GBT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Global Blood Therapeutics Inc (NASDAQ:GBT).

Institutional Ownership by Quarter for Global Blood Therapeutics (NASDAQ:GBT)

Receive News & Ratings for Global Blood Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global Blood Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.